Unraveling the Complexity of Endocrine Resistance in Breast Cancer by Functional Genomics  by Swanton, Charles & Downward, Julian
Cancer Cell
PreviewsUnraveling the Complexity  
of Endocrine Resistance  
in Breast Cancer by Functional Genomics
Charles Swanton1,2,* and Julian Downward1,*
1Cancer Research UK London Research Institute, Signal Transduction Laboratory, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK
2Royal Marsden Hospital, Department of Medicine, Fulham Road, London SW3 6JJ, UK
*Correspondence: swanton@cancer.org.uk (C.S.); downward@cancer.org.uk (J.D.)
DOI 10.1016/j.ccr.2008.01.021
Despite the proven benefit of antiestrogen drugs in breast cancer treatment, resistant disease ultimately 
develops in advanced breast cancer. In this issue of Cancer Cell, Iorns et al. find that loss of CDK10 
expression promotes resistance of cells to tamoxifen and is associated with poor outcome in breast 
cancer patients treated with the drug. CDK10 loss increases the activity of the transcription factor ETS2 
on the promoter of the RAF1 gene, elevating ERK/MAPK kinase pathway activity and relieving tamoxifen-
induced G1 arrest. CDK10 is thus a potential biomarker for sensitivity in prospective clinical trials of 
patients treated with endocrine therapies.Tamoxifen is one of the most success-
ful agents used in the management of 
hormone receptor-positive breast can-
cer. In trials of adjuvant treatment with 
tamoxifen in early breast cancer fol-
lowing surgery, the absolute improve-
ments in 10-year survival were 10.9% for node-positive and 5.6% for node-
negative patients (EBCTCG, 2005). Its 
use improves quality of life in patients 
with estrogen receptor (ER)-positive 
advanced (metastatic) breast cancer, 
often delaying the need for cytotoxic 
chemotherapy. Despite its success and Figure 1. Endocrine Resistance Mediated by Signal Transduction Cascades
Tamoxifen induces a G1 cell cycle arrest. Activation of signal transduction molecules associated with 
resistance to endocrine therapies (red) or sensitivity (blue) affects progression through the G1/S phase 
of the cell cycle. CDK10 loss drives ERK pathway activity through transcriptional upregulation by ETS2 
of c-Raf-1. ETS2 also induces senescence through p16INK4A. STIs targeting this pathway (black) may 
enhance endocrine response.Cancer Cestatus as one of the most active agents 
available for patients with this disease, 
the development of tamoxifen resis-
tance is almost inevitable in patients 
with advanced disease, and up to 40% 
of patients treated with tamoxifen in the 
adjuvant setting suffer disease relapse.
Laboratory studies have demon-
strated that activation of EGF receptor 
family and the ERK/MAPK pathway pro-
mote estrogen-independent growth (see 
Figure 1), leading to several clinical tri-
als using signal transduction inhibitors 
(STIs) to enhance endocrine sensitivity 
(Johnston et al., 2007). These trials have 
met with limited success, emphasizing 
the requirement to define novel endo-
crine resistance pathways and establish 
mechanisms through which established 
signaling axes may be activated in order 
to optimize the selection of patients for 
future trials. This may lead to the devel-
opment of improved approaches to pro-
long benefit from endocrine agents and 
to select patients who may benefit from 
the use of alternative treatment strate-
gies targeting the endocrine axis.
With this in mind, Ashworth and col-
leagues (Iorns et al., 2008) have devel-
oped an RNA interference (RNAi) 
screening approach to identify kinases 
involved in the acquisition of tamoxifen 
resistance in a well-described ER-posi-
tive breast cancer cell line, MCF-7. The 
authors transfect these cells with syn-
thetic small interfering (si) RNAs target-ll 13, February 2008 ©2008 Elsevier Inc. 83
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and related proteins, assaying the effect 
on cell proliferation over a week in the 
presence or absence of tamoxifen. Iorns 
et al. have identified three genes whose 
knockdown reproducibly caused resis-
tance to tamoxifen treatment: cyclin-
dependent kinase 10 (CDK10), CDC2-
related protein kinase 7 (CRK7) and 
mitogen-activated protein kinase kinase 
7 (MAP2K7).
Concentrating on a thorough exami-
nation of the role of CDK10 in cellular 
responsiveness to tamoxifen, the authors 
show that effective silencing of this 
kinase induces resistance to ERα signal-
ing and overcomes a G1 cell cycle arrest 
in response to tamoxifen treatment by 
subverting cyclin D1 expression. Impor-
tantly, Iorns et al. provide evidence that 
tamoxifen resistance conferred by CDK10 
suppression does not result in increased 
expression or activation of ERα and that 
expression of ER target genes are not 
induced, so tamoxifen resistance is not 
conferred by ligand-independent ERα 
activation. Furthermore, CDK10 silencing 
also confers resistance to a relatively new 
antiestrogen agent used in clinical prac-
tice, fulvestrant, or ICI 182,780, which 
induces ERα degradation.
The authors proceed to define the 
pathway of resistance to tamoxifen 
mediated through CDK10 suppression. 
A likely suspect in the hunt to con-
nect tamoxifen resistance with cyclin 
D1 expression was the ERK pathway, 
activation of which has been shown to 
result in increased cyclin D1 expres-
sion (Lavoie et al., 1996). Activation of 
the pathway components ERK1/2 and 
MEK1/2 was observed following CDK10 
silencing, while suppression of ERK 
pathway signaling at the same time as 
CDK10 inhibition restored sensitivity to 
tamoxifen. As for proteins upstream of 
MEK, both the level and activity of the 
upstream kinase c-Raf-1 were increased 
following CDK10 silencing.
Given the increased c-Raf-1 mRNA wit-
nessed in cells lacking CDK10, an obvi-
ous suspect that might be responsible for 
these aberrant transcriptional effects was 
the ETS2 transcription factor, implicated 
by its previously documented associa-
tion with CDK10 (Kasten and Giordano, 
2001) and with tamoxifen resistance in 
breast cancer through ERK1/2 signal-84 Cancer Cell 13, February 2008 ©2008 Eing (Svensson et al., 2005). CDK10 has 
been shown to inhibit the transactiva-
tion capacity of ETS2 (Kasten and Gior-
dano, 2001), so CDK10 loss would be 
predicted to potentiate ETS2-mediated 
gene transcription. Again, resistance 
could be partially overcome following 
cosuppression of ETS2 and CDK10, and 
the authors provide evidence confirming 
their association in MCF-7 cells. Are the 
couple guilty by association, or is ETS2 
directly implicated in c-Raf-1 transcrip-
tional activation? Chromatin immunopre-
cipitation experiments here place CDK10 
and ETS2 on the RAF1 gene promoter, 
while loss of CDK10 potentiates ETS2 
interaction with the promoter.
This presents a compelling model 
(see Figure 1). However, ETS2 is a rela-
tively promiscuous transcription factor 
and may also potentiate growth arrest 
through the induction of the broad CDK 
inhibitor p21CIP1 (Beier et al., 1999) and 
senescence through the induction of 
the CDK4/6 inhibitor p16INK4A (Ohtani et 
al., 2001). This is particularly relevant as 
the MCF-7 cells used here display bial-
lelic loss of CDKN2A, the gene encod-
ing p16INK4A, which has been shown to 
confer resistance to ETS1- or ETS2-
induced senescence (Huot et al., 2002). 
Furthermore, recent evidence implicates 
pRb as a nodal regulator of antiestrogen 
responsiveness (Varma et al., 2007) as 
pRb inactivation results in antiestrogen 
resistance, and expression of AIB1, a 
nuclear receptor coactivator, impairs 
tamoxifen-induced cell cycle arrest by 
potentiating E2F1 activity (a target of 
pRb-mediated repression) (Louie et al., 
2004). Does CDK10 influence ETS2 inter-
action with the CDKN2A promoter and 
p16INK4A expression in a manner similar to 
what is seen in this study with c-Raf-1? 
Similar experiments characterizing the 
effects of CDK10 silencing in estrogen-
responsive breast cancer cell lines with 
wild-type p16INK4A will be interesting; a 
targeted approach toward ETS2 inacti-
vation in order to potentiate tamoxifen 
responsiveness could in principle induce 
a paradoxical effect, limiting oncogene-
induced senescence and conceivably 
potentiating endocrine resistance.
Nevertheless, in two separate clini-
cal data sets of breast cancer patients 
treated with adjuvant tamoxifen, Ash-
worth and colleagues demonstrate that lsevier Inc.low CDK10 expression is associated 
with a statistically significant shorter 
time to distant relapse and, in one data 
set, poorer overall survival. These data 
are compelling, particularly as CDK10 
expression appears to have no associ-
ation with HER2 status or level of ERα 
expression, and may represent a new 
biomarker of endocrine responsiveness 
worthy of follow-up in prospective stud-
ies. It will be interesting to assess whether 
CDK10 expression affects disease-free 
survival in estrogen receptor-positive 
patients only (as might be predicted from 
this study), or whether CDK10 loss con-
fers poorer prognosis regardless of ER 
status. It might be predicted that CDK10 
loss in tumors (potentiating ETS2-medi-
ated transactivation) could segregate 
with biallelic mutations in CDKN2A, 
which ablate a cellular defense mecha-
nism against oncogene-induced senes-
cence. Could CDK10 loss play a role in 
the acquisition of hormone-refractory 
prostate cancer, a disease that displays 
altered regulation of the ETS family of 
transcription factors including ETS2, 
potentially driving c-Raf-1 expression 
and androgen independence (Mukherjee 
et al., 2005)?
This study provides a compelling 
connection between a previously known 
signal transduction pathway associated 
with resistance to endocrine therapies 
and a poorly studied cyclin-dependent 
kinase associated with worse outcome 
following tamoxifen treatment in vivo. It 
demonstrates once again the power of 
RNA interference screens as a means 
to deciphering the basic biological 
mechanisms underlying the behavior of 
cancer cells. A remaining challenge is to 
identify the significance of ETS pathway 
activation in prospective clinical stud-
ies and to identify molecules capable 
of effectively limiting pathway activity to 
prolong endocrine responsiveness.
REFEREnCES
Beier, F., Taylor, A.C., and LuValle, P. (1999). J. Biol. 
Chem. 274, 30273–30279.
Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG). (2005). Lancet 365, 1687–1717.
Huot, T.J., Rowe, J., Harland, M., Drayton, S., 
Brookes, S., Gooptu, C., Purkis, P., Fried, M., Ba-
taille, V., Hara, E., et al. (2002). Mol. Cell. Biol. 22, 
8135–8143.
Cancer Cell
PreviewsIorns, E., Turner, N.C., Elliott, R., Syed, N., Garrone, 
O., Gasco, M., Tutt, A.N.J., Crook, T., Lord, C.J., 
and Ashworth, A. (2008). Cancer Cell, this issue.
Johnston, S.R., Leary, A., Martin, L.A., Smith, I.E., 
and Dowsett, M. (2007). Cancer 112, 710–717.
Kasten, M., and Giordano, A. (2001). Oncogene 
20, 1832–1838.
Lavoie, J.N., L’Allemain, G., Brunet, A., Muller, R., The term “multiple myeloma” was sug-
gested by von Rustizky in 1873, when 
he found during autopsy multiple sepa-
rate bone marrow (myel-) tumors (-oma ) 
(Malpas et al., 2004). Multiple myeloma 
(MM) is a post-germinal center tumor 
of long-lived bone marrow (BM) plas-
mablasts/plasma cells (PC) that have 
undergone extensive somatic hypermu-
tation of Ig heavy chain (IgH) and Ig light 
chain (IgL) genes, antigen selection, and 
productive IgH switch recombination. 
Most tumors produce IgG or IgA, with 
IgM produced by only 1% of tumors. MM 
usually is preceded by a similarly age-
dependent premalignant tumor called 
monoclonal gammopathy of undeter-
mined significance (MGUS), the most 
common lymphoid tumor in humans, 
occurring in nearly 3% of individuals 
over the age of 50. For MGUS, the serum 
monoclonal Ig (M-Ig) typically is 5–30 g/l 
(normal polyclonal Ig is 7–15 g/l), with 
the tumor cells comprising no more than 
10% of BM mononuclear cells. Although 
MGUS usually remains stable for many 
Modeling Multiple
Conditional Activa
W. Michael Kuehl1,*
1Genetics Branch, National Cancer Institute, B
*Correspondence: wmk@helix.nih.gov
DOI 10.1016/j.ccr.2008.01.022
Efforts to create a mouse model that
unsuccessful. In this issue of Cance
problem by creating a model in whic
sequences is activated sporadically 
reverts the stop codon. Although mu
likely to impact the creation of sporaand Pouyssegur, J. (1996). J. Biol. Chem. 271, 
20608–20616.
Louie, M.C., Zou, J.X., Rabinovich, A., and Chen, 
H.W. (2004). Mol. Cell. Biol. 24, 5157–5171.
Mukherjee, R., Bartlett, J.M., Krishna, N.S., Under-
wood, M.A., and Edwards, J. (2005). Prostate 64, 
101–107.
Ohtani, N., Zebedee, Z., Huot, T.J., Stinson, Cancer C
years, there can be sporadic progres-
sion to frankly malignant MM express-
ing the same M-Ig at a rate of 1% per 
year. Smoldering MM, with a stable BM 
content of 10%–30% tumor cells, has 
a higher rate of sporadic progression. 
Frankly malignant MM usually is pro-
gressive and is associated with second-
ary pathologies, sometimes including 
osteoporosis, osteolytic lesions, ane-
mia, immunodeficiency, and decreased 
kidney function. Similar to long-lived PC, 
MGUS and MM have a strong depen-
dence on the BM microenvironment 
for survival and growth, although some 
individuals develop extramedullary MM, 
or PC leukemia, most often as a very 
late event. In contrast to long-lived PC, 
MGUS and MM have the ability to prolif-
erate at a low rate, usually with only a few 
percent of cycling cells until advanced 
stages of MM.
Early oncogenic events that are 
shared by MGUS and MM include pri-
mary IgH translocations (40%) and 
hyperdiploidy (50%), with dysregula-
 Myeloma by AID
tion of MYC
ethesda, MD 20889, USA
 provides even a phenocopy of huma
r Cell, Bergsagel and colleagues d
h a MYC transgene containing a sto
in germinal center B cells by AID-de
ch remains to be done to fully char
dic models for other kinds of germinJ.A., Sugimoto, M., Ohashi, Y., Sharrocks, A.D., 
Peters, G., and Hara, E. (2001). Nature 409, 
1067–1070.
Svensson, S., Jirstrom, K., Ryden, L., Roos, G., 
Emdin, S., Ostrowski, M.C., and Landberg, G. 
(2005). Oncogene 24, 4370–4379.
Varma, H., Skildum, A.J., and Conrad, S.E. 
(2007). PLoS ONE 2, e1256. 10.1371/journal.
pone.0001256.ell 13, February 2008 ©2008 Elsevier Inc. 85
tion of a CYCLIN D gene being a uni-
fying event for all tumors (Chng et al., 
2007). Based on these early events, it 
has been proposed that MGUS and MM 
can be classified into at least five dis-
tinct molecular groups (diseases) that 
are associated with different biological 
and clinical characteristics. No genetic 
abnormalities distinguish MM and 
MGUS, although activating RAS muta-
tions occur in 30%–40% of MM tumors 
but only 5% of MGUS tumors. Among 
shared genetic events that occur dur-
ing progression of MM, rearrangements 
of MYC (rarely MYCN) represent a very 
late progression event that appears to 
be associated with increased prolifera-
tion and decreased stromal cell depen-
dence.
The development of animal models 
for MM, including both de novo and 
syngeneic (Vanderkerken et al., 2003) 
or xenogenic (human MM into SCID-
Hu, SCID-Rab, or NOD-SCID mice) 
(Matsui et al., 2008; Yata and Yac-
coby, 2004) mouse transplant models 
-Dependent 
n multiple myeloma (MM) have been 
escribe an apparent solution to this 
p codon and flanking Igκ regulatory 
pendent somatic hypermutation that 
acterize this model, this approach is 
al center B cell tumors.
